Business context and reporting period
INVO Bioscience, Inc. (the registrant named in the filing; the request metadata says INVO Fertility) filed this Form 10-K for the fiscal year ended December 31, 2021. The company commercializes INVOcell, a device used in intravaginal culture (IVC), and is developing a model combining device sales, distribution partnerships, and dedicated INVO fertility centers. Three centers—in Alabama, Georgia, and Mexico—opened during 2021; the Mexico center began initial treatment cycles in January 2022.
Financial performance and condition
| Metric | 2021 | 2020 |
|---|---|---|
| Revenue | $4.16 million | $1.04 million |
| Gross profit / margin | $4.02 million / 97% | $0.95 million / 91% |
| Operating expenses | $9.23 million | $6.46 million |
| Operating loss | $5.22 million | $5.51 million |
| Net loss | $6.65 million | $8.35 million |
| Cash used in operations | $6.03 million | $4.78 million |
| Cash and cash equivalents at year-end | $5.68 million | $10.10 million |
| Working capital | $5.1 million | $8.3 million |
2021 revenue comprised $544,942 of product sales, $43,745 of clinic revenue, and $3.57 million of license revenue. The license amount largely reflects recognition of remaining deferred revenue after Ferring gave notice to terminate its U.S. distribution agreement. Thus, the 301% revenue increase does not by itself demonstrate comparable growth in recurring product or clinic sales. SG&A increased 49% to $9.02 million, including $2.7 million of non-cash stock-based compensation. Interest expense and financing fees were $1.27 million, down from $2.84 million.
Cash used in investing activities was $2.15 million, primarily for equipment and investments in INVO Centers; financing activities provided $3.77 million, mainly from common-stock sales and option and warrant exercises. The company reported $7.31 million of stockholders’ equity. The 2020 convertible notes had been converted or repaid by year-end 2021, and the PPP loan was forgiven. Operating lease liabilities totaled $2.12 million. The company reported federal net operating loss carryforwards of approximately $25.8 million, with a full valuation allowance against net deferred tax assets.
Material changes versus the prior year
- Revenue increased substantially, chiefly because of the Ferring termination-related license revenue recognition; product revenue rose to $545,000 from $323,000.
- Net loss narrowed by about $1.69 million, while operating cash use increased by about $1.25 million and year-end cash fell by about $4.41 million.
- SG&A rose by approximately $2.95 million, reflecting higher stock compensation, personnel costs, Georgia JV operations, and startup and legal costs.
- The company opened Alabama and Georgia centers and a Mexico center, and invested in new center operations and equipment.
- Common shares outstanding increased to 11.93 million from 9.64 million, including shares issued for financing, debt conversion, services, and an acquisition.
Outlook, commentary, and key risks
Management plans to open additional INVO Centers and sell directly to established U.S. fertility clinics following the Ferring agreement’s termination on January 31, 2022. The company also intends to expand international distribution and pursue FDA label expansion for up to five-day incubation; its prospective clinical trial had been placed on hold during the COVID-19 pandemic, while a retrospective-data 510(k) effort remained ongoing. No quantified revenue, profitability, or cash-flow guidance is provided.
The independent auditor issued an unmodified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. The company has a long history of losses, expects continued spending and losses while commercializing its product and centers, and states that additional financing may be needed; funding may not be available on acceptable terms. It may need to reduce or delay operations if it cannot raise capital or generate sufficient operating cash.
- Revenue concentration and transition: Ferring termination removes the U.S. distributor and its minimum-purchase commitments; 2021 reported revenue included a significant termination-related recognition.
- Financing and dilution: Continued cash consumption and a thin, volatile stock market may constrain capital raising; new debt or equity could dilute shareholders or impose restrictive obligations.
- Execution and JV exposure: Center ramp-up, partner performance, funding commitments, and the ability to achieve profitable clinic operations remain uncertain. Alabama and Mexico JVs recorded losses.
- Regulatory and clinical risks: FDA and foreign-market compliance, product quality, and the outcome and timing of the five-day label-expansion effort could affect commercialization.
- Other risks: Competition, limited reimbursement, reliance on third-party manufacturing, intellectual-property protection, healthcare privacy and compliance obligations, and foreign-exchange exposure.
Subsequent events include the termination of the Paradigm stock purchase agreement after only $315,000 was received against a larger commitment, and termination of the India JV agreement in March 2022 after the partner could not meet its commitments.
Important facts for investors to verify
- How much of future revenue comes from recurring product sales and clinic operations, rather than the Ferring-related license recognition?
- What is the company’s current cash runway and financing plan, given 2021 operating cash use of $6.03 million and the auditor’s going-concern warning?
- What are the centers’ patient volumes, cycle outcomes, revenue, cash needs, and path to profitability?
- What commercial impact followed the Ferring transition, including customer retention, direct-sales execution, and replacement of minimum-purchase support?
- What is the current status, evidence base, and expected timing for FDA clearance of the five-day incubation label expansion?
- How have subsequent financing, share issuance, and JV developments affected cash, debt, and fully diluted share count?